PA5-29673
antibody from Invitrogen Antibodies
Targeting: MYH9
DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [6]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-29673 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MYH9 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein fragment
- Description
- Recommended positive controls: 293T, A431, HeLa, HepG2, NIH-3T3, BCL-1, Raw264.7, C2C12, Rat2. Predicted reactivity: Mouse (98%), Rat (97%), Xenopus laevis (91%), Dog (99%), Chicken (95%), Bovine (99%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.43 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references circATP2A2 promotes osteosarcoma progression by upregulating MYH9.
Cao X, Meng X, Fu P, Wu L, Yang Z, Chen H
Open medicine (Warsaw, Poland) 2021;16(1):1749-1761
Open medicine (Warsaw, Poland) 2021;16(1):1749-1761
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MYH9 using A) 30 µg 293T whole cell lysate (B) 30 µg A431 whole cell lysate (C) 30 µg HeLa whole cell lysate and D) 30 µg HepG2 whole cell lysate. Samples were loaded onto a 5% SDS-PAGE gel and probed with a MYH9 polyclonal antibody (Product # PA5-29673) at a dilution of 1:1000.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of MYH9 was performed by separating 30 µg of various whole cell extracts by 5% SDS-PAGE. Proteins were transferred to a membrane and probed with a MYH9 Polyclonal Antibody (Product # PA5-29673) at a dilution of 1:1000 and a HRP-conjugated anti-rabbit IgG secondary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of MYH9 was performed by separating 30 µg of various whole cell extracts by 5% SDS-PAGE. Proteins were transferred to a membrane and probed with a MYH9 Polyclonal Antibody (Product # PA5-29673) at a dilution of 1:1000 and a HRP-conjugated anti-rabbit IgG secondary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- MYH9 Polyclonal Antibody detects MYH9 protein by western blot analysis. A. 30 µg NIH-3T3 whole cell lysate/extract. B. 30 µg BCL-1 whole cell lysate/extract. C. 30 µg Raw264.7 whole cell lysate/extract. D. 30 µg C2C12 whole cell lysate/extract.5% SDS-PAGE. MYH9 Polyclonal Antibody (Product # PA5-29673) dilution: 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- MYH9 Polyclonal Antibody detects MYH9 protein by western blot analysis. A. 30 µg Rat2 whole cell lysate/extract.5% SDS-PAGE. MYH9 Polyclonal Antibody (Product # PA5-29673) dilution: 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-MYH9 Polyclonal Antibody (Product # PA5-29673) and a 226kDa band corresponding to MYH9 was observed in Mouse Heart and was not present in Mouse Lung. Tissue extracts (30 µg lysate) of Mouse Heart (Lane 1) and Mouse Lung (Lane 2) were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0322BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L), Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry-Immunofluorescence analysis of MYH9 was performed in HeLa cells fixed in ice-cold MeOH for 5 min. Green: MYH9 Polyclonal Antibody (Product # PA5-29673) diluted at 1:500. Blue: Hoechst 33342 staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (Paraffin) analysis of MYH9 was performed in paraffin-embedded human breast carcinoma tissue using MYH9 Polyclonal Antibody (Product # PA5-29673) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (Paraffin) analysis of MYH9 was performed in paraffin-embedded mouse prostate tissue using MYH9 Polyclonal Antibody (Product # PA5-29673) at a dilution of 1:400.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of MYH9 was performed in HeLa whole cell extracts using 5 µg of MYH9 Polyclonal Antibody (Product # PA5-29673). Samples were transferred to a membrane and probed with MYH9 Polyclonal Antibody as a primary antibody and an HRP-conjugated anti-Rabbit IgG was used as a secondary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 MiR-335-5p targeted MYH9. (a-c) The levels of MYH9 mRNA and protein in OS tissues were analyzed by RT-qPCR, western blotting, and IHC. (d) The level of MYH9 protein in OS cells was analyzed by western blotting. (e) The binding sites between MYH9 and miR-335-5p were predicted by the starBase database. (f and g) The luciferase activities of the reporter plasmids carrying MYH9 3'UTR-wt and MYH9 3'UTR-mut were determined with dual-luciferase reporter assay. (h and i) The abundance of miR-335-5p and MYH9 in the immunoprecipitates of the anti-Ago2 and anti-IgG groups was assessed by RT-qPCR. (j) The impacts of miR-335-5p overexpression and silencing on the level of MYH9 protein were analyzed by Western blotting. (k) The level of MYH9 protein in OS cells transfected with sh-NC + anti-NC, sh-circATP2A2 + anti-NC, or sh-circATP2A2 + anti-miR-335-5p was detected by Western blotting. * P < 0.05.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 MiR-335-5p targeted MYH9 to inhibit OS cell malignancy and glycolysis. (a) The overexpression efficiency of MYH9 in OS cells was detected by Western blotting. (b-k) OS cells were transfected with miR-NC + vector, miR-335-5p + vector, or miR-335-5p + MYH9. (b-h) The proliferation, cell cycle progression, migration, and invasion of OS cells were evaluated by MTT, plate clone, flow cytometry, and transwell assays, respectively. (i and j) Detection of glucose uptake and lactate product levels in OS cells. (k) Analysis of HK2 and PKM2 protein levels in U2OS and Saos-2 cells by Western blotting. * P < 0.05.